The IGFBP5 Knockout TE1 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal cell population derived from the human esophageal squamous cell carcinoma line TE1, featuring targeted disruption of the IGFBP5 gene. This polyclonal knockout model provides a genetically heterogeneous population of cells with diverse loss-of-function mutations, enabling robust functional studies of IGFBP5 in a physiologically relevant cancer cell background.
The TE1 cell line, established from a human esophageal squamous cell carcinoma, serves as a well-characterized model of epithelial cancer, exhibiting aggressive growth properties and genetic alterations typical of esophageal malignancies. As an adherent cell line derived from a primary tumor, TE1 retains key signaling pathways driving tumorigenesis, making it particularly suitable for investigating molecular mechanisms underlying esophageal squamous cell carcinoma progression, metastasis, and therapeutic resistance.
IGFBP5 encodes a secreted insulin-like growth factor binding protein that tightly regulates the bioavailability and activity of IGF-I and IGF-II, thereby modulating the IGF1R-mediated activation of downstream cascades including PI3K/AKT/mTOR and MAPK/ERK signaling. Beyond its canonical IGF-binding function, IGFBP5 exerts IGF-independent effects on cell proliferation, differentiation, apoptosis, and migration through interactions with cell surface integrins and fibronectin, as well as transcriptional regulation by TP53 and TGF-??. The loss of IGFBP5 disrupts this multifaceted network, altering the phosphorylation status of key nodes such as AKT and ERK, and impacting the expression of BCL2 family proteins and matrix metalloproteinases, ultimately affecting cell survival and invasive capacity.
In the context of esophageal squamous cell carcinoma, IGFBP5 plays a context-dependent role, with evidence suggesting both tumor-suppressive and oncogenic activities. IGFBP5 knockout in TE1 cells enables dissection of its precise contribution to esophageal cancer hallmarks, including sustained proliferative signaling, evading apoptosis, and activating invasion and metastasis. This model is particularly valuable for exploring how IGFBP5 loss influences the response to growth factors like IGF-I and TGF-??, and how crosstalk between the PI3K/AKT and MAPK pathways is rewired in the absence of IGFBP5. Additionally, since TP53 mutations are frequent in esophageal cancers, the interplay between p53 status and IGFBP5 function can be investigated using this knockout background.
Researchers can utilize this polyclonal knockout population for western blotting and RT-qPCR to confirm target gene disruption and to quantify changes in IGF1R phosphorylation, AKT activation, and downstream targets. Functional assays such as MTT or BrdU proliferation tests, transwell migration and invasion chambers, and Annexin V apoptosis analysis provide robust platforms for dissecting IGFBP5??s role in cell growth, motility, and survival. The model is also well-suited for drug resistance studies, as the dysregulated IGF signaling cascade often mediates resistance to chemotherapeutic agents and targeted therapies. For further technical information and to discuss customized applications, please contact Ascent Research.
